心血管

订阅

MedSci主页 / 所有栏目 / 心血管

一文掌握：PCI术后出血风险管理三大要点

2022-03-22 小菲e学 网络

出血风险
关注

鉴于PCI术后出血受到多方面因素影响，对于合并不同危险因素的患者需给以个体化抗栓治疗，本文主要介绍老年患者、房颤患者、卒中病史患者、亚洲人群的个体化治疗特征。

MAT-CN-2204236

有效期至2024年3月

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1633872, encodeId=422e16338e252, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Thu May 19 21:30:04 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486461, encodeId=f4361486461bb, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu Mar 24 07:30:04 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542285, encodeId=d82b154228559, content=<a href='/topic/show?id=863d10089e30' target=_blank style='color:#2F92EE;'>#风险管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100897, encryptionId=863d10089e30, topicName=风险管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a78313401027, createdName=膀胱癌, createdTime=Thu Mar 24 07:30:04 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
    2022-05-19 zxl736

    #PCI术#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1633872, encodeId=422e16338e252, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Thu May 19 21:30:04 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486461, encodeId=f4361486461bb, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu Mar 24 07:30:04 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542285, encodeId=d82b154228559, content=<a href='/topic/show?id=863d10089e30' target=_blank style='color:#2F92EE;'>#风险管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100897, encryptionId=863d10089e30, topicName=风险管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a78313401027, createdName=膀胱癌, createdTime=Thu Mar 24 07:30:04 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
    2022-03-24 12499e01m49暂无昵称

    #PCI术后#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1633872, encodeId=422e16338e252, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Thu May 19 21:30:04 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486461, encodeId=f4361486461bb, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu Mar 24 07:30:04 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542285, encodeId=d82b154228559, content=<a href='/topic/show?id=863d10089e30' target=_blank style='color:#2F92EE;'>#风险管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100897, encryptionId=863d10089e30, topicName=风险管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a78313401027, createdName=膀胱癌, createdTime=Thu Mar 24 07:30:04 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
    2022-03-24 膀胱癌

    #风险管理#

    0

相关资讯

Nat Commun：阿司匹林的替代药？科学家研制出不会增加出血风险的合成血液抗凝剂！

患有肺栓塞、缺血性中风和心肌梗塞等由于血栓形成而导致疾病的患者，通常会服用阿司匹林和氯吡格雷等“血液稀释剂”药物，以阻止血凝块形成或增大，帮助血液顺畅流动，防止疾病进一步的发展。

双抗期间院外出血风险评估（PRECISE-DAPT score）

双抗期间院外出血风险评估（PRECISE-DAPT score）

ESC 2020线上访谈丨单一抗血小板治疗：对早期使用的见解——Dominick Angioliiio教授

鉴于抗血小板药物的广泛应用以及其出血风险，进一步认识抗血小板药物（包括单抗和双抗）的安全性是非常重要的。尤其是最近有研究强调在PCI患者中早期单一抗血小板治疗。

探需求，循证据，论古稀耄耋——老年房颤患者抗凝策略探讨

房颤是一种年龄相关性疾病，以老年人居多，老年房颤患者有几个特点：高血栓和高出血风险并存，肝、肾功能减退，合并症多，合并用药多。因此对药物的安全性、代谢、药代动力学、药物相互作用、便利性等有更高的要求。

NEJM：高出血风险患者PCI方案选择——聚合物药物洗脱支架 vs 无聚合物药物涂层支架

在PCI后1个月接受双重抗血小板治疗的高出血风险患者中，使用聚合物Zotarolimus洗脱支架在安全性和有效性方面与无聚合物药物涂层支架相当

Front Cardiovasc Med：HAS-BLED评分对AF患者出血风险的预测分析

心房颤动（AF）是临床实践中最常见的心律失常，与缺血性卒中的5倍风险相关。口服抗凝剂（OAC）可降低AF患者发生血栓栓塞的风险；然而，也增加出血风险。